Posts

Showing posts from 2014

The 10 Largest Pharmaceutical Companies In the World

Hi all,             Came across a lit of 10 largest pharmaceutical companies in the world. Worth noting. The collective biotech and pharmaceutical industry is known to be one of the most active and wealthy industries in the world, considering the global pharmaceutical market is worth about $1 trillion. Furthermore, within modern societies, the increased usage of medicines and medications for treating almost every illness (or perceived illness) is likely to keep raising demand for these products, and thus continue bursting pharmaceutical companies’ sales and revenue. SN Company Country Revenue 1 Johnson & Johnson USA USD 71.3 Billion 2 Novartis Switzerland USD 60.9 Billion 3 Roche Switzerland USD 52.4 Billion 4 Pfizer USA USD 51.6 Billion 5 Sanofi France USD 45.8 Billion 6 Merck USA USD 44.0 Billion 7 GlaxoSmithKline UK USD 43.9 Billion 8 AstraZeneca UK USD 27.2 Billion 9 Elli Lilly USA

QIP_Frontiers in Pharmacology of Drug research & Recent trends in pharmacy practice

AICTE Sponsored Quality Improvement Programme is being organized by Manipal College of Pharmaceutical Sciences, Manipal University, Manipal – 576104, Karnataka. The two-week programme is designed to provide a fine mix of lectures and demonstrations. Resources persons from host departments and other institutions with expertise in their fields will deliver lectures meant to give an insight into innovative drug development. There have been several advances in drug development in the recent past. This programme will familiarize the participants with these and the emerging trends in drug development. There would be demonstrations of experiments with sophisticated instruments involving cell culture techniques, Elisa and Flow cytometer etc.   The details are as follows: Theme: Frontiers in Pharmacology of Drug research & Recent   trends in Pharmacy Practice.   Dates:  5 th to 17 th January 2015.   Organized by: Manipal College of Pharmaceutical Sciences, Manipal Unive

Thomson Reuters’ India Innovation Awards 2014 for Sun pharma and Biocon

Biocon and Sun Pharma were honoured at Thomson Reuters’ India Innovation Awards 2014, announced at the recent launch of its 2014 State of Innovation India report. This is the second consecutive year of the study, which analyses innovation in 12 leading sectors based on patent activity for inventions originating from India, using the Derwent World Patents Index, Thomson Reuters’ proprietary patent database. Hi-tech engineering and pharma companies emerged as front runners of innovation in India. The study showcases twelve leading sectors and analyses the innovation in each based on patent activity. “India is an important global innovation hub, with both local and global organizations conducting critical R&D activities in India. Patenting activity is growing rapidly and this has a direct impact on the country’s economic growth,” said Pradeep Lankapalli, Managing Director, India and head of global operation centres, Thomson Reuters India. The India Innovation Awards

Two Days National Conference on Drug Discovery and Drug Targeting in Metabolic Diseases

Shri Vile Parle Kelavani Mandal’s Dr. Bhanuben Nanavati College of Pharmacy is organizing “Two Days National Conference on Drug Discovery and Drug Targeting in Metabolic Diseases” in Mumbai.   There is a powerful interplay of nutrition and metabolic alterations that lead to metabolic disorders. A large proportion of metabolic disorders go largely undetected due to lack of awareness. Metabolic disorders have a disproportionately high prevalence in the Indian population. Cardiovascular diseases, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes.   The sessions are aimed to discuss the impact of this paradigm change in the way drugs are discovered, developed and targeted in the metabolic diseases arena and to stay abreast of the latest targets and drug development candidates in the pipeline.   The details are as follows: The

Journal Impact factors

Hi All, We publish so many articles in so many journals. Usually number of publications is considered as the criteria about the research experience in academics. However, what plays more role is the quality of journal which is determined by Impact factor.   You must have heard about Impact Factor of a journal. What it is?   Wikipedia defines " The impact factor (IF)" of an academic journal is a measure reflecting the average number of citations to recent articles published in that journal. It is frequently used as a proxy for the relative importance of a journal within its field, with journals with higher impact factors deemed to be more important than those with lower ones. The impact factor was devised by Eugene Garfield , the founder of the Institute for Scientific Information . Impact factors are calculated yearly starting from 1975 for those journals that are indexed in the Journal Citation Reports.   The Impact factor of any journal is available onlin

QbD in Pharma Development World Congress 2015

The 3rd Annual International conference “QbD in Pharma Development World Congress 2015” is being organized this year in Chandigarh. The event will feature experts who are adept in this science and risk-based approaches, and therefore, will offer definitive benefits to the scientists from academia and industry working in the domains of Product Development, Process R & D, Scale-up, Manufacturing, Quality Assurance, Global Regulatory Affairs, API, Excipients, Pharmaceutical Analysis and Technology Transfer. The speakers will articulate on all the pertinent areas of QbD Implementation including Manufacturing, Formulation, Analytical Development and Excipients. The details are as follows: Theme:               "Emerging Challenges, Federal Issues & Possible Solutions" . Dates:                 April 16-18, 2015. Location:             Hotel Shivalik View, Chandigarh, India . Details available at: http://selectbiosciences.com/conferences/index.aspx?conf=QPDWC15

First batch of Pharm.D pass-outs gets lucrative placements

Pharmabiz reports that most of the well-known Pharm.D institutes and colleges in the country have successfully provided placements to the first batch of Pharm.D pass-outs, with some of them gearing up to find lucrative jobs in the market, thanks to the focus on patient-oriented rather than product-oriented Pharm.D course.   “Several aspirants have chosen to travel overseas for their careers hoping to find careers in community and hospital settings. Since there is a great demand for starting of Pharm.D programme in the institutions, they are also finding careers in academic settings,” Dr B Suresh, vice chancellor, JSS University, Mysore & president, Pharmacy Council of India, New Delhi, confirms to Pharmabiz.         Source: http://www.pharmabiz.com/NewsDetails.aspx?aid=85531&sid=1

7th International Symposium on Drug Metabolism & PharmacoKinetics

7th International Symposium on Drug Metabolism & PharmacoKinetics is being organized in NIPER, Mohali.   This is primarily a lecture-based symposium intended for students and scientists from industry, academia,  health-based government organizations, and healthcare professionals with a background in chemistry, biology,  and the pharmaceutical sciences, with some experience in the principles and techniques of drug metabolism  and pharmacokinetics.  The symposium is also intended for experienced researchers in these areas who wish to broaden or supplement their area of expertise, as well as contribute to the discussion topics. The details are as follows: Theme:            7th International Symposium on Drug Metabolism & PharmacoKinetics. Dates:               February 18-21, 2015. Organized by:     NIPER. Location:             Mohali, Punjab. Details available at: http://www.niper.ac.in/dmpk2015/HOME.html

Applied Pharmaceutical Analysis-India

The Boston Society® is an internationally-recognized non-profit organization and is dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. It is organizing “Applied Pharmaceutical Analysis-India” in Mumbai.   The details are as follows: Theme:             Increasing Size, Complexity and Potency: The Bioanalytical Challenges of the Next Decade. Dates:               February 22-25, 2015. Organized by:   The Boston Society® Location:           Mumbai. Details available at: http://www.bostonsociety.org/APA-India/

National Conference on “ Drug Carriers in Medicine and Biology

Department of Biotechnology, Bannari Amman Institute of Technology, Sathyamangalam is organizing a National Conference on “Drug Carriers in Medicine and Biology” during 7-8 January 2015, supported by Science and Engineering Research Board/ Department of Science and Technology and Department of Biotechnology/Ministry of Science and Technology, Government of India, New Delhi. The details are as follows: Theme:             National Conference on “Drug Carriers in Medicine and Biology”.   Dates:                January 7-8 , 2015. Organized by:     Department of Biotechnology, Bannari Amman Institute of Technology, Sathyamangalam. Location:           Sathyamangalam - 638 401, Erode District, Tamilnadu, India.   Details available at: http://www.bitsathy.ac.in/dcmb2015.pdf    

Competition comission clears Sun-Ranbaxy deal but tells it to sell off 7 brands

Firstpost reports that the drug-makers Sun Pharma and Ranbaxy got fair trade watchdog CCI's {Competition commission of India} approval on Monday for their long-pending USD 4-billion merger, but with a condition that they will have to modify the deal by divesting seven key products to address monopoly concerns. This move would create the country's largest pharmaceutical company post the merger between Sun Pharma and Ranbaxy Laboratories. Under the conditions, Sun Pharma will divest products involving Lueprorelin. The divest products will include Tamplet and Lupride . On the other hand, Ranbaxy Laboratories will divest products such as Raciper L, Terlibax, Triolvance, Olanex F and Rosuvas EZ. Source: http://firstbiz.firstpost.com/corporate/cci-clears-sun-ranbaxy-deal-but-tells-it-to-sell-off-7-brands-112308.html http://zeenews.india.com/business/news/companies/cci-approves-sun-pharma-ranbaxy-deal-creates-india-s-largest-pharma-co_113679.html  

PHARMACY COUNCIL OF INDIA - NOTIFICATION

The recent government notification published details about the "Minimum requirements of academic qualifications, teaching, research and industry experience for teaching posts in pharmacy colleges/institutions".   Diploma course: Name of Post Academic qualification Teaching/Research/Industry experience Principal/Director/ Head of institute/ Head of department PCI recognized Post Graduate qualification in any discipline of pharmaceutical sciences. OR PCI recognized Pharm. D. Essential: 5 years teaching experience in PCI approved/recognized Pharmacy College. Desirable: Administrative experience in a responsible position. Lecturer (Pharmacy subjects) PCI recognized M.Pharm/ Pharm. D. OR PCI recognized B. Pharm (i) A person holding M.B.B.S. qualification can be considered for the pos

12th National Pharmaceutical Conclave

CII and DIPP are organizing "12th National Pharmaceutical Conclave" in New Delhi. The conclave intends to focus on the issues that need urgent attention of the industry stakeholders. Further, it endeavours to bring the decision makers together so that the discussions result in meaningful actionable outcomes. The details are as follows: Theme:                         Make, Develop and Innovate in India. Dates:                          12 th and 13 th December 2014. Organized by:               CII and DIPP, Government of India.   Location:                      New Delhi. Details available at:         http://www.nationalpharmaconclave.com/index.php        

Department of Pharmaceuticals pondering over price monitoring cells

The Department of Pharmaceuticals is considering setting up price monitoring cells in all states to provide technical assistance to drug controllers and the National Pharmaceutical Pricing Authority (NPPA).  The price monitoring cells will render technical assistance to State Drug Controllers and NPPA in monitoring the notified price of medicines, price movement of scheduled/non-scheduled formulations, collection/monitoring availability of drugs as required under provisions of DPCO.